Tumorigenic activity and therapeutic inhibition of Rheb GTPase
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The AKT–mTOR pathway harbors several known and putative oncogenes and tumor suppressors. In a phenotypic screen for lymphomagenesis, we tested candidate genes acting upstream of and downstream from mTOR in vivo. We find that Rheb, a proximal activator of mTORC1, can produce rapid development of aggressive and drug-resistant lymphomas. Rheb causes mTORC1-dependent effects on apoptosis, senescence, and treatment responses that resemble those of Akt. Moreover, Rheb activity toward mTORC1 requires farnesylation and is readily blocked by a pharmacological inhibitor of farnesyltransferase (FTI). In Pten-deficient tumor cells, inhibition of Rheb by FTI is responsible for the drug’s anti-tumor effects, such that a farnesylation-independent mutant of Rheb renders these tumors resistant to FTI therapy. Notably, RHEB is highly expressed in some human lymphomas, resulting in mTORC1 activation and increased sensitivity to rapamycin and FTI. Downstream from mTOR, we examined translation initiation factors that have been implicated in transformation in vitro. Of these, only eIF4E was able to enhance lymphomagenesis in vivo. In summary, the Rheb GTPase is an oncogenic activity upstream of mTORC1 and eIF4E and a direct therapeutic target of farnesyltransferase inhibitors in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Cells were untreated or treated twice with rapamycin 100 nM and collected 7 d post-selection for immunoblotting and senescence-associated -galactosidase (SA -Gal) as described (Serrano et al. 1997).”
BackgroundMethodSelf-citationDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · cited 1×
“Cellular senescence is an important failsafe mechanism against transformation and is directly induced by certain oncogenes including Ras, Akt, and eIF4E (Serrano et al. 1997; Ruggero et al. 2004; Chen et al. 2005).”
BackgroundRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 5×
“Mice receiving HPCs expressing wild-type Rheb or Rheb/ Q64L, an allele with increased activity toward mTORC1, developed tumors with high penetrance and short latency compared with vector controls or an inactive Rheb mutant (Rheb/5A) (Fig.”
BackgroundMethodInfluentialMaurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881 · cited 3×
“Viability was determined by trypan blue stain and TUNEL assay as described (McCurrach and Lowe 2001).”
MethodInfluentialTee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827 · cited 2×
“Several genetic lesions upstream of mTOR have been identified that can activate the AKT pathway, and these include mutations in PI3k, AKT/ PKB, or loss of the tumor suppressors PTEN, TSC1, or TSC2 (for review, see Vivanco and Sawyers 2002).”
BackgroundmTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607 · cited 4×
“…the unique role of eIF4E as a translation factor capable of driving tumor development in vivo and are consistent with a rate-limiting role of eIF4E in the translation of transformation-relevant proteins (Polunovsky et al. 2000; Hay and Sonenberg 2004; Wendel et al. 2004; Mamane et al. 2007).”
BackgroundInfluentialDissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487 · cited 8×
“In particular, eIF4E’s dual regulation by the Akt and Mapk pathways may be amenable to targeted inhibitors of these signaling pathways (Silva and Wendel 2007; Wendel et al. 2007).”
BackgroundMethodResultInfluentialSelf-citationRajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420 · cited 5×
“Conversely, c-Myc can interfere with the induction of cellular senescence by Rheb and Akt as well as eIF4E (Ruggero et al. 2004).”
BackgroundInfluential
Research works printed but not linked: 45
- 10.1016/j.ccr.2004.05.024 · DOI · Paper page
- 10.1074/jbc.M503763200 · DOI · Paper page
- 10.1111/j.1365-2141.2008.07099.x · DOI
- 10.1016/j.bbrc.2006.03.220 · DOI · Paper page
- Burnett,, 2007, Tipifarnib in acute myeloid leukemia, Drugs Today (Barc), 43, 795, 10.1358/dot.2007.43.11.1088617 · doi:10.1358/dot.2007.43.11.1088617
- 10.1038/sj.onc.1207544 · DOI · Paper page
- Dilling,, 1994, Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor, Cancer Res., 54, 903
- Donze,, 1995, Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells, EMBO J., 14, 3828, 10.1002/j.1460-2075.1995.tb00052.x · DOI · Paper page
- 10.1126/science.1130276 · DOI · Paper page
- Du,, 1999, Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors, Cancer Res., 59, 5492
- 10.1038/sj.onc.1207738 · DOI
- 10.1016/0092-8674(92)90123-T · DOI · Paper page
- Fukuchi-Shimogori,, 1997, Malignant transformation by overproduction of translation initiation factor eIF4G, Cancer Res., 57, 5041
- 10.1158/1535-7163.MCT-04-0347 · DOI · Paper page
- 10.1101/gad.1212704 · DOI · Paper page
- 10.1128/MCB.00289-08 · DOI · Paper page
- 10.1038/sj.onc.1205792 · DOI
- 10.1083/jcb.jcb.200206108 · DOI · Paper page
- 10.1200/JCO.2004.08.082 · DOI
- 10.1182/blood-2006-04-014357 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-0752 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-0421 · DOI · Paper page
- 10.1038/345544a0 · DOI · Paper page
- 10.4161/cc.3.10.1196 · DOI · Paper page
- 10.1073/pnas.1332764100 · DOI · Paper page
- 10.1101/gad.1314405 · DOI · Paper page
- 10.1038/sj.onc.1207549 · DOI · Paper page
- 10.1371/journal.pone.0000242 · DOI · Paper page
- 10.1101/gad.1314605 · DOI · Paper page
- McCurrach,, 2001, Methods for studying pro- and antiapoptotic genes in nonimmortal cells, Methods Cell Biol., 66, 197, 10.1016/S0091-679X(01)66010-2 · DOI
- 10.1002/gcc.10025 · doi:10.1002/gcc.10025
- 10.1074/jbc.M010551200 · DOI · Paper page
- 10.1074/jbc.M001938200 · DOI · Paper page
- 10.1038/nm1042 · DOI · Paper page
- 10.1016/S1535-6108(02)00047-8 · DOI · Paper page
- Silva,, 2007, MNK, EIF4E and targeting translation for therapy, Cell Cycle, 7, 553, 10.4161/cc.7.5.5486 · DOI
- 10.1016/j.ccr.2006.08.022 · DOI · Paper page
- 10.1016/j.molcel.2007.11.018 · DOI · Paper page
- 10.1038/348331a0 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-0917 · DOI · Paper page
- 10.1038/nrc839 · DOI · Paper page
- 10.1038/nature02369 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-0419 · DOI · Paper page
- 10.1101/gad.1212504 · DOI
- 10.1261/rna.7191905 · DOI · Paper page
Cited by
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Self-citationTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
“Similarly, RHEB is overexpressed in some lymphomas, which have increased mTOR activity and enhanced sensitivity to FTI”
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607
Self-citationOrtega-Molina, A., Boss, I. W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. (2015) · Nature Medicine · doi:10.1038/nm.3943 · Cited by 436
Self-citation
Metadata
- Authors
- Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H.-G.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2008-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 2178-2188
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2119540996
- Cited by
- 113
- References
- 14
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumorigenic activity and therapeutic inhibition of Rheb GTPase. https://app.cochat.ai/papers/10.1101/gad.1690808
- The paper
- Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H.-G. (2008). Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes & Development. https://doi.org/10.1101/gad.1690808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.